| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| Furthermore , we demonstrate a novel translocation in this tumor , the t ( 5 ; 9 ) ( q 31 ; p 24 ) , that possibly led to fusion of the interleukin 3 ( IL 3 ) ( 5q31 ) and JAK 2 ( 9p24 ) genes and may explain the concomitant appearance of eosinophilia and ALL . . ^^^ |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| The 145 kDa protein , which appears , from antiphosphotyrosine blots of two dimensional O ' Farrell gels , to exist in four different phosphorylation states following cytokine stimulation ( with isoelectric points ranging from 7 . 2 to 7 . 8 ) , does not appear to be immunologically related to the beta subunit of the interleukin 3 receptor , c Kit , BCR , ABL , JAK 1 , JAK 2 , Sos 1 , eps 15 , or insulin receptor substrate 1 protein . ^^^ |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| Bcr / gp130 is capable of interacting with JAK 1 , JAK 2 , and TYK 2 ; is constitutively active ; and induces gene expression through IL 6 responsive elements . ^^^ However , Bcr / gp130DeltaTM initiates partial signaling in the presence of overexpressed JAK 1 and TYK 2 , but not JAK 2 . ^^^ |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| A BCR JAK 2 fusion gene as the result of a t ( 9 ; 22 ) ( p 24 ; q11 . 2 ) translocation in a patient with a clinically typical chronic myeloid leukemia . ^^^ By means of a candidate gene approach , the JAK 2 gene , at 9p24 , was identified as the fusion partner of BCR in this case . ^^^ The BCR JAK 2 fusion protein contains the coiled coil dimerization domain of BCR and the protein tyrosine kinase domain ( JH 1 ) of JAK 2 . ^^^ The patient ' s disease did not respond to Imatinib , and this unresponsiveness was most likely a result of the BCR JAK 2 fusion protein . . ^^^ |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| Furthermore , tyrosine phosphorylated Jak 2 was detected in blood cells from CML patients in blast crisis but not in a normal marrow sample . ^^^ |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| We have previously shown that the Jak 2 tyrosine kinase is activated in Bcr Abl positive cell lines and blood cells from CML blast crisis patients by tyrosine phosphorylation . ^^^ |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| JAK 2 mutation 1849G > T is rare in acute leukemias but can be found in CMML , Philadelphia chromosome negative CML , and megakaryocytic leukemia . ^^^ JAK 2 mutation was also detected in 3 ( 19 % ) of 16 patients with Philadelphia chromosome ( Ph ) negative chronic myelogenous leukemia ( CML ) , 2 ( 18 % ) of 11 patients with megakaryocytic AML , 7 ( 13 % ) of 52 patients with chronic myelomonocytic leukemia , and 1 ( 1 % ) of 68 patients with myelodysplastic syndromes . ^^^ |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| Absence of the JAK 2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR ABL positive CML in chronic phase and blast crisis . ^^^ In this study , we examined highly enriched CD34+ cells from patients with BCR ABL positve CML in chronic phase or blast crisis for the JAK 2 V617F activation mutation by sequencing . ^^^ This finding suggests that the previously described increase of expression and kinase activity of JAK 2 in CML cells does not result from the JAK 2 V617F activation mutation and that transformation into blast crisis is not associated with the occurrence of this mutation . . ^^^ |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| Treatment of CML cell lines and mouse Bcr Abl+ 32D cells with either Jak 2 short interfering RNA or Jak 2 kinase inhibitor AG 490 inhibited pTyr Gab 2 and pSer Akt formation , inhibited the activation of nuclear factor kappaB , and caused the activation of GSK 3beta , leading to the reduction of c Myc . ^^^ These results identify Jak 2 as a potentially important therapeutic target for CML . . ^^^ |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P11274 and O60674 |
Pubmed |
SVM Score :0.0 |
| NA |
|